Jurkat T-Cell Receptor (TCR) alpha/beta-Knockout Cell Line

Description

Jurkat TCR α/β-Knockout CD8 Cells

30% introductory discount until December 31, 2025

The Cellecta Jurkat TCRa/b-Knockout CD8 cell line is a clonal Jurkat cell line in which its endogenous T-cell receptor was knocked out by CRISPR/Cas9 genome editing on both alpha and beta chains.

• Clonal derivative of the Jurkat E6.1 line, no selection marker
• CRISPR-edited to knock out endogenous TCR α/β chains
• For transduction with any transgenic TCR constructs
• Designed to facilitate high-fidelity assays for T-cell activation
• Express CD8 (important to stabilize TCR-MHC interaction by increased TCR-R-pMHC affinity and boosting TCR signaling)

Applications:

This cell line can be used for expressing any gene-specific TCR for target peptide testing or screening.

TCR Cloning and Evaluation:  Jurkat TCR Knockout Cells can be used to analyze the target peptide specificity and affinity of both, native and engineered TCRs, transduced into the cells by a lentiviral expression vector.

TCR Screening and Validation:  Use with Cellecta’s engineered K562 Puro or BFP Antigen Presenting Cell Lines for TCR screening and co-culturing assays

Antigen Screening:  Libraries of specific peptides can be screened against TCR-expressing Jurkat TCR knock out cells to identify those recognized by particular TCRs, as well as analysis of antibodies or small molecules that can mimic or inhibit TCR activation.

T Cell Signaling Studies:  Jurkat TCR Knockout Cells can be used to study T-cell pathway responses to tumor- or virus-specific antigens and to dissect the molecular mechanisms underlying T-cell activation